Chinese Journal of Pharmacovigilance ›› 2025, Vol. 22 ›› Issue (2): 162-168.
DOI: 10.19803/j.1672-8629.20240536

Previous Articles     Next Articles

Possible Molecular Mechanisms of Dachengqi Decoction for Improving Subjective Symptoms of Degenerative Lumbar Spinal Stenosis: a Network Pharmacology Study

GAN Yena1,2, HAN Sheng1,2, YUAN Yi3, XUE Lijuan4, HUANG Haowen4, LI Huanxin4, ZHANG Xinci4, KUI Siyi4, MENG Bofei4, LI Qifei4, ANARGUL Tudi4, LIU Zhifeng4, QIN Lingling4, LI Duoduo4,*   

  1. 1School of Pharmaceutical Science, Peking University, Beijing 100191, China;
    2International Research Center for Medicinal Administration, Peking University, Beijing 100191, China;
    3Centre for Evidence-Based Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;
    4Department of Tuina and Pain, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
  • Received:2024-07-30 Online:2025-02-17 Published:2025-02-17

Abstract: Objective To explore the molecular mechanisms of Dachengqi decoction in the treatment of degenerative lumbar spinal stenosis (DLSS) using a network pharmacology approach. Methods The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was searched to retrieve information on the chemical components and genes related to Dachengqi decoction as of July 10, 2024. For compounds not covered by TCMSP or without target gene information, the molecular formulas were obtained from the PubChem database, and SwissADME was used for screening. Target prediction for eligible compounds was performed using the SwissTargetPrediction database, and gene names were standardized using the UniProt database. On the same day, the GenCards, OMIM, and DrugBank databases were searched to collect information on DLSS-related disease genes, which was then mapped to the drug targets. Common genes were imported into the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database to construct a protein-protein interaction (PPI) network, followed by pathway enrichment analysis using the Metascape database. Cytoscape 3.10.2 software was used to create a “drug-compound-target” network, and NetworkAnalyzer was applied for topological analysis of key compounds and targets. Results Ten key active compounds, including rutin, 5,7,4'-trimethylapigenin, and eucalyptol, as well as ten key targets, including prostaglandin-endoperoxide synthase 2 (PTGS2) and heat shock protein β (HSPCB), were identified. Pathway enrichment analysis suggested that Dachengqi decoction could improve the subjective symptoms of DLSS patients through the PI3K-Akt signaling pathway, AGE-RAGE signaling pathway, neurodegeneration pathway, and various cellular activities. Conclusion Dachengqi decoction can not only alleviate constipation and related symptom exacerbation in DLSS patients, but also modulate inflammation, oxidative stress, and nerve cell tissue repair through its active compounds, targets, and pathways.

Key words: Dachengqi Decoction, Rutin, 5,7,4'-trimethylapigenin, Eucalyptol, Degenerative Lumbar Spinal Stenosis, Network Pharmacology

CLC Number: